These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16756417)

  • 1. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
    Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans.
    Stoops WW; Lile JA; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2005 Feb; 13(1):56-64. PubMed ID: 15727504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans.
    Rush CR; Stoops WW; Hays LR; Glaser PE; Hays LS
    J Pharmacol Exp Ther; 2003 Jul; 306(1):195-204. PubMed ID: 12676890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
    Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazepam does not modulate the behavioral effects of d-amphetamine in humans.
    Lile JA; Stoops WW; Wagner FP; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2005 Oct; 82(2):270-9. PubMed ID: 16182353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse liability assessment of atomoxetine in a drug-abusing population.
    Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
    Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
    Rush CR; Madakasira S; Goldman NH; Woolverton WL; Rowlett JK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):174-88. PubMed ID: 8996195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.
    Wee S; Woolverton WL
    Drug Alcohol Depend; 2004 Sep; 75(3):271-6. PubMed ID: 15283948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans.
    Lile JA; Stoops WW; Vansickel AR; Glaser PE; Hays LR; Rush CR
    Neuropsychopharmacology; 2005 Nov; 30(11):2103-14. PubMed ID: 15988473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotine as a conditioned stimulus: impact of attention-deficit/hyperactivity disorder medications.
    Reichel CM; Linkugel JD; Bevins RA
    Exp Clin Psychopharmacol; 2007 Oct; 15(5):501-9. PubMed ID: 17924784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans.
    Oliveto AH; Rosen MI; Woods SW; Kosten TR
    J Pharmacol Exp Ther; 1995 Jan; 272(1):231-41. PubMed ID: 7815337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.
    Rush CR; Kollins SH; Pazzaglia PJ
    Exp Clin Psychopharmacol; 1998 Feb; 6(1):32-44. PubMed ID: 9526144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual differences in responses to ethanol and d-amphetamine: a within-subject study.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 2001 Apr; 25(4):540-8. PubMed ID: 11329494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.
    Sevak RJ; Stoops WW; Hays LR; Rush CR
    J Pharmacol Exp Ther; 2009 Mar; 328(3):1007-18. PubMed ID: 19104030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain.
    Easton N; Steward C; Marshall F; Fone K; Marsden C
    Neuropharmacology; 2007 Feb; 52(2):405-14. PubMed ID: 17020775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.